Lluis Montoliu to give a talk on science communication at UPV/EHU on May 6, sharing insights on how to effectively disseminate research from the lab.
Vitoria-Gasteiz, may 2025. Lluis Montoliu, renowned researcher from the Spanish National Research Council (CSIC) and expert in biomedical communication, will deliver a talk titled “Keys to Communicating and Disseminating from Research Laboratories” at the Micaela Portilla Research Centre, University of the Basque Country (UPV/EHU), Campus of Álava. The event will take place from 12:00 to 13:30h in the main auditorium.
Montoliu is a senior researcher at the Centro Nacional de Biotecnología (CNB-CSIC), member of the executive committee of the CIBERER (Center for Biomedical Research on Rare Diseases), and a leading voice in public science outreach. He is also affiliated with our researchers from Unit 10 of NANBIOSIS, the Drug Formulation Unit, which is hosted at the Faculty of Pharmacy of the University of the Basque Country (UPV/EHU) in Vitoria-Gasteiz.
NANBIOSIS Unit 10, led by Prof. José Luis Pedraz, is a cutting-edge platform specialized in the design and evaluation of classical and advanced drug delivery systems, including biotech drugs, DNA, RNA, and vaccines. The Unit stands out for its expertise in micro- and nanoencapsulation of cells, peptides, proteins, and gene therapy vectors. Uniquely, this Unit is GLP-certified, underscoring its compliance with the highest standards of quality and reliability in pharmaceutical development. The Unit provides comprehensive support for all stages of formulation development.
This event is open to all interested in science communication, research dissemination, and pharmaceutical technology. Registration is required and can be completed by contacting angela_losada@ehu.eus.
What is NANBIOSIS?
The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).
In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.
NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:
